Suchergebnisse - "Freyer, Gilles"

PubPharm (245)

1

Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Bouvarel, B. | Colomban, O. | Frenel, J. | +6

2

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer : The randomized Tempo Breast study

enthalten in: Breast (Edinburgh, Scotland) | 2024

von Freyer, G. | Martinez-Jañez, N. | Kukielka-Budny, B. | +17

3

Progression-free survival and safety at 3.5 years of follow-up : results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary

enthalten in: Future oncology (London, England) | 2024

von González-Martín, A. | Pothuri, B. | Vergote, I. | +15

4

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer : a phase II clinical trial from the GINECO group

enthalten in: Nature communications | 2024

von Freyer, G. | Floquet, A. | Tredan, O. | +10

5

Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA

enthalten in: JCO clinical cancer informatics | 2024

von Carrot, A. | Oudard, S. | Colomban, O. | +5

6

Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence

enthalten in: Geburtshilfe und Frauenheilkunde | 2024

von Fasching, P. | Kreipe, H. | Del Mastro, L. | +7

7

Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting"

enthalten in: Journal of gynecologic oncology | 2024

von van Wagensveld, L. | Colomban, O. | van der Aa, M. | +4

8

Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

enthalten in: Bulletin du cancer | 2023

von Gligorov, J. | Benderra, M. | Barthere, X. | +60

9

enthalten in: Bulletin du cancer | 2023

von Freyer, G.

10

Progression-free survival and safety at 3.5years of follow-up : results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von González-Martín, A. | Pothuri, B. | Vergote, I. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[25]